U.S. FDA approves Celgene's Abraxane for pancreatic cancer
Sept 6 (Reuters) - Celgene Corp's drug Abraxane was approved as a treatment for pancreatic cancer by the U.S. Food and Drug Administration on Friday.
Abraxane is currently approved to treat breast cancer and non-small cell lung cancer. In a clinical trial, patients with pancreatic cancer who received Abraxane plus the chemotherapy gemcitabine lived, on average, 1.8 months longer than those who received gemcitabine alone.
- Target holiday cyber breach hits 40 million payment cards
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Zuckerberg to sell Facebook shares worth about $2.3 billion
- Home sales tumble, jobless claims at near nine-month high
- Special Report: Why Ukraine spurned the EU and embraced Russia